Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W. Flaherty LE, et al. Among authors: fisher ri. J Clin Oncol. 2001 Jul 1;19(13):3194-202. doi: 10.1200/JCO.2001.19.13.3194. J Clin Oncol. 2001. PMID: 11432886 Clinical Trial.
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
Parkinson DR, Fisher RI, Rayner AA, Paietta E, Margolin KA, Weiss GR, Mier JW, Sznol M, Gaynor ER, Bar MH, et al. Parkinson DR, et al. Among authors: fisher ri. J Clin Oncol. 1990 Oct;8(10):1630-6. doi: 10.1200/JCO.1990.8.10.1630. J Clin Oncol. 1990. PMID: 2213100 Clinical Trial.
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
Gaynor ER, Weiss GR, Margolin KA, Aronson FR, Sznol M, Demchak P, Grima KM, Fisher RI, Boldt DH, Doroshow JH, et al. Gaynor ER, et al. Among authors: fisher ri. J Natl Cancer Inst. 1990 Sep 5;82(17):1397-402. doi: 10.1093/jnci/82.17.1397. J Natl Cancer Inst. 1990. PMID: 2388289
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.
Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, et al. Sparano JA, et al. Among authors: fisher ri. J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):216-23. doi: 10.1097/00002371-199410000-00006. J Immunother Emphasis Tumor Immunol. 1994. PMID: 7834121 Clinical Trial.
334 results